Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans

  • Meijian Guan (Contributor)
  • Jacob M. Keaton (Creator)
  • Latchezar Dimitrov (Creator)
  • Pamela J. Hicks (Creator)
  • Jianzhao Xu (Contributor)
  • Nicholette D. Palmer (Creator)
  • Lijun Ma (Contributor)
  • Swapan K. Das (Creator)
  • Yii Der Ida Chen (Contributor)
  • Josef Coresh (Creator)
  • Myriam Fornage (Creator)
  • Nora Franceschini (Creator)
  • Holly J. Kramer (Creator)
  • Carl D. Langefeld (Creator)
  • Josyf Mychaleckyj (Contributor)
  • Rulan S. Parekh (Contributor)
  • Wendy S. Post (Creator)
  • Laura J Rasmussen-Torvik (Creator)
  • Stephen S. Rich (Creator)
  • Jerome I. Rotter (Creator)
  • J. Sedor (Creator)
  • Denyse Thornley-Brown (Creator)
  • Adrienne Tin (Creator)
  • James G. Wilson (Creator)
  • Barry I. Freedman (Creator)
  • Donald W. Bowden (Creator)
  • Maggie C.Y. Ng (Creator)



Abstract Background End-stage kidney disease (ESKD) is a significant public health concern disproportionately affecting African Americans (AAs). Type 2 diabetes (T2D) is the leading cause of ESKD in the USA, and efforts to uncover genetic susceptibility to diabetic kidney disease (DKD) have had limited success. A prior genome-wide association study (GWAS) in AAs with T2D-ESKD was expanded with additional AA cases and controls and genotypes imputed to the higher density 1000 Genomes reference panel. The discovery analysis included 3432 T2D-ESKD cases and 6977 non-diabetic non-nephropathy controls (N = 10,409), followed by a discrimination analysis in 2756 T2D non-nephropathy controls to exclude T2D-associated variants. Results Six independent variants located in or near RND3/RBM43, SLITRK3, ENPP7, GNG7, and APOL1 achieved genome-wide significant association (P 
Date made available2019

Cite this